TY - JOUR
T1 - A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts
AU - Bao, Ying
AU - Giovannucci, Edward L.
AU - Kraft, Peter
AU - Stampfer, Meir J.
AU - Ogino, Shuji
AU - Ma, Jing
AU - Buring, Julie E.
AU - Sesso, Howard D.
AU - Lee, I. Min
AU - Gaziano, John Michael
AU - Rifai, Nader
AU - Pollak, Michael N.
AU - Cochrane, Barbara B.
AU - Kaklamani, Virginia
AU - Lin, Jennifer H.
AU - Manson, Joann E.
AU - Fuchs, Charles S.
AU - Wolpin, Brian M.
N1 - Funding Information:
The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services (contracts N01WH22110, 24152, 32100–2, 32105–6, 32108–9, 32111– 13, 32115, 32118–32119, 32122, 42107–26, 42129–32, and 44221).
Funding Information:
The PHS I is supported by the National Institutes of Health (grants CA 97193, CA 34944, CA 40360, HL 26490, and HL 34595).
Funding Information:
The NHS and HPFS are supported by the National Cancer Institute, National Institutes of Health (grants P01 CA87969, P01 CA55075, P50 CA127003, R01 CA124908). BMW is supported by NCI K07 CA140790; an American Society of Clinical Oncology Career Development Award; a Howard Hughes Medical Institute Early Career Physician-Scientist Award; and the Lustgarten Foundation.
Funding Information:
The work is also supported in part by a donation from the Conquer Cancer Coalition of Massachusetts.
Funding Information:
The WHS is supported by the National Institutes of Health (grants CA047988, HL043851, and HL080467).
PY - 2013/1/16
Y1 - 2013/1/16
N2 - Background The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood. Methods To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subjects from five prospective US cohorts: Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. Control subjects were matched to case subjects by prospective cohort, year of birth, smoking status, fasting status, and month of blood draw. All samples for plasma adiponectin were handled identically in a single batch. Odds ratios were calculated with conditional logistic regression, and linearity of the association between adiponectin and pancreatic cancer was modeled with restricted cubic spline regression. All statistical tests were two-sided. Results Median plasma adiponectin was lower in case subjects versus control subjects (6.2 vs 6.8 μg/mL, P =. 009). Plasma adiponectin was inversely associated with pancreatic cancer risk, which was consistent across the five prospective cohorts (Pheterogeneity =. 49) and independent of other markers of insulin resistance (eg, diabetes, body mass index, physical activity, plasma C-peptide). Compared with the lowest quintile of adiponectin, individuals in quintiles 2 to 5 had multivariable odds ratios ([ORs] 95% confidence intervals [CIs]) of OR = 0.61 (95% CI = 0.43 to 0.86), OR = 0.58 (95% CI = 0.41 to 0.84), OR = 0.59 (95% CI = 0.40 to 0.87), and OR = 0.66 (95% CI = 0.44 to 0.97), respectively (Ptrend =. 04). Restricted cubic spline regression confirmed a nonlinear association (Pnonlinearity <. 01). The association was not modified by sex, smoking, body mass index, physical activity, or C-peptide (all Pinteraction >. 10). Conclusions In this pooled analysis, low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer.
AB - Background The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood. Methods To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subjects from five prospective US cohorts: Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. Control subjects were matched to case subjects by prospective cohort, year of birth, smoking status, fasting status, and month of blood draw. All samples for plasma adiponectin were handled identically in a single batch. Odds ratios were calculated with conditional logistic regression, and linearity of the association between adiponectin and pancreatic cancer was modeled with restricted cubic spline regression. All statistical tests were two-sided. Results Median plasma adiponectin was lower in case subjects versus control subjects (6.2 vs 6.8 μg/mL, P =. 009). Plasma adiponectin was inversely associated with pancreatic cancer risk, which was consistent across the five prospective cohorts (Pheterogeneity =. 49) and independent of other markers of insulin resistance (eg, diabetes, body mass index, physical activity, plasma C-peptide). Compared with the lowest quintile of adiponectin, individuals in quintiles 2 to 5 had multivariable odds ratios ([ORs] 95% confidence intervals [CIs]) of OR = 0.61 (95% CI = 0.43 to 0.86), OR = 0.58 (95% CI = 0.41 to 0.84), OR = 0.59 (95% CI = 0.40 to 0.87), and OR = 0.66 (95% CI = 0.44 to 0.97), respectively (Ptrend =. 04). Restricted cubic spline regression confirmed a nonlinear association (Pnonlinearity <. 01). The association was not modified by sex, smoking, body mass index, physical activity, or C-peptide (all Pinteraction >. 10). Conclusions In this pooled analysis, low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84872590843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872590843&partnerID=8YFLogxK
U2 - 10.1093/jnci/djs474
DO - 10.1093/jnci/djs474
M3 - Article
C2 - 23243202
AN - SCOPUS:84872590843
SN - 0027-8874
VL - 105
SP - 95
EP - 103
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -